ArticleMolecular cancer2025
The landscape of dynamic tumor immunophenotyping on neoadjuvant chemotherapy combined with trastuzumab for the treatment of HER2-positive breast cancer.
Article in Molecular cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metabolic Subtypes Predict Treatment Response in Acute Myeloid Leukemia: A Pilot Study.Blood and lymphatic cancer : targets and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
backgroundFor HER2-positive breast cancer (BC), patients who achieve pathologic complete response (pCR) are predicted to have better clinical outcomes. With the advent of the era of neoadjuvant chemotherapy (NAC) combined with targeted therapy, the pCR rate of HER2-positive BC has increased significantly, but about 50% of these patients still do not respond to targeted therapy. The dynamic changes in the tumor microenvironment (TME) may crucially influence pCR outcomes in HER2-positive BC. However, there is no specific immunophenotyping study that correlates with the efficacy during treatment.
methodsWe conducted a comprehensive spatial expression profiling analysis on 94 ROIs procured from 28 HER2-positive BC patients, encompassing both their initial diagnostic stage and postoperative status. Leveraging DSP techniques, we precisely mapped and quantified the TME at these critical time points for patients.
resultsNotably, we classified specimens into four groups: IM1, IM2, TM1, and TM2. IM1 and TM1, characterized by CD4⁺ naïve T cells and naïve B cells, showed higher pCR rates, whereas IM2 and TM2 exhibited lower rates. In addition, baseline IM1 patients who were classified as TM1 postoperatively achieved a 100% pCR rate, while baseline IM2 patients who were classified as TM2 postoperatively had a poor pCR rate of only 10%. The immunophenotypes defined by spatial transcriptomics were reproducible in both TCGA and single-cell datasets, and spatial analysis further revealed structured cellular transitions and functional heterogeneity at the tumor-immune interface.
conclusionOur dynamic immunophenotyping can provide prediction of the efficacy for NAC with trastuzumab in HER2-positive BC patients, and provide a basis for the selection of subsequent treatment regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.